Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on May 19, 2021 1:02pm
141 Views
Post# 33230661

RE:RE:Neil Warma

RE:RE:Neil Warma

One person has been with PMN from the beginning, His unwillingness to part from any of his creations may have been the reason for that director resignation and moved into other ventures, after all he was brought in to achieved that ..

Since last summer a new direction has taking place and maybe the new found partnerships show that willingness is beginning to show , with partnerships the likes  of Dr Wishart or Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), or BCNI 
 Time is ruining out for some of this board members as age is catching up , maybe is time to leave a mark on their legacy ..

farmerjane wrote: Yes a General Manager of I-Mab, with many levels of authority above him and what ownership? I seem to recall Promis had a director for a number of years that sold a company prior for plus/minus a billion $ that resigned last fall.  Didn't help Promis get anywhere with there science!

 

<< Previous
Bullboard Posts
Next >>